H
Human Immunology Biosciences
Biotechnology company focused on developing therapies for immune-mediated diseases
About Human Immunology Biosciences
HI Bio is a clinical-stage biotechnology company focused on developing targeted therapies for patients suffering from severe immune-mediated diseases (IMDs). Leveraging human genetic and immunological insights, HI Bio aims to deliver precision medicine solutions that address the root causes of these complex conditions. The company operates in the biopharmaceutical market, primarily serving healthcare providers and patients who require advanced therapeutic options for immune system dysfunctions. HI Bio's business model revolves around research and development, clinical trials, and eventual commercialization of its proprietary therapies. Revenue is generated through a combination of funding rounds, partnerships, and future sales of approved treatments. The company recently secured $95 million in Series B financing to advance its pipeline of targeted therapies.
Source: Dealroom company dataAt a glance
- Founded
- 2021
- Headquarters
- San Francisco, United States
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
ARCH Venture Partners
Monograph Capital
Jeito Capital
Alpha Wave Global
Arkin Capital
Viking Global Investors
Series B and later3 investors entered at this stage
- ACArkin Capital
- Alpha Wave Global
- VIViking Global Investors
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Human Immunology Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Human Immunology Biosciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.